ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander Sells 5,555 Shares

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander sold 5,555 shares of the company’s stock in a transaction on Monday, May 19th. The stock was sold at an average price of $138.00, for a total value of $766,590.00. Following the sale, the chief operating officer now owns 2,389 shares of the company’s stock, valued at approximately $329,682. This represents a 69.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

ICU Medical Trading Down 2.4%

ICU Medical stock opened at $138.00 on Tuesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock has a market cap of $3.40 billion, a PE ratio of -30.20 and a beta of 0.87. The stock has a 50-day moving average of $140.78 and a two-hundred day moving average of $153.61. ICU Medical, Inc. has a one year low of $100.91 and a one year high of $196.26.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.49. The firm had revenue of $599.49 million for the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.96 earnings per share. On average, research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ICUI shares. KeyCorp decreased their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Raymond James lowered their price target on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a report on Friday, May 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $192.67.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Harvest Fund Management Co. Ltd purchased a new position in shares of ICU Medical in the fourth quarter worth $33,000. Quarry LP increased its position in shares of ICU Medical by 764.3% in the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 214 shares during the period. Murphy & Mullick Capital Management Corp purchased a new position in ICU Medical in the 4th quarter worth $52,000. Venturi Wealth Management LLC lifted its position in ICU Medical by 64.0% during the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock worth $82,000 after acquiring an additional 206 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.